用潜在风险模型提前预测临床试验成败,提升研发决策效率。
A Latent Risk-Aware Machine Learning Approach for Predicting Operational Success in Clinical Trials based on TrialsBank
- 构建两级潜变量风险模型,利用180多个早期可得特征预测试验风险。
- 在I-III期试验中预测准确率F1达0.93~0.91,显著提升失败识别能力。
- 适合制药公司和临床研发团队用于早期试错评估与资源优化。
临床试验成本高、周期长且运营风险大,但启动前可靠的前瞻性成功率预测方法仍有限。现有AI方法多聚焦单一指标或特定阶段,且依赖设计阶段无法获取的变量,实用性受限。本文提出一种分层潜变量风险感知机器学习框架,基于Sorintellis构建的专有数据库TrialsBank(含13,700项试验)进行前瞻性预测。操作成功定义为按计划启动、执行并完成试验,直至数据锁定。该框架将预测分为两步:先用180多个试验与药物级特征预测中间潜变量风险,再整合至下游模型估算成功概率。采用分阶段数据划分防止信息泄露,并以XGBoost、CatBoost及可解释增强机为基准。在I-III期试验中,该框架实现0.93、0.92、0.91的外样本F1分数,引入潜变量风险后显著提升失败判别力,独立推理下性能依然稳健。结果表明,通过潜变量风险感知框架可有效前瞻性预测试验成功,支持早期风险评估与数据驱动研发决策。
原文摘要 · Abstract (English)
Clinical trials are characterized by high costs, extended timelines, and substantial operational risk, yet reliable prospective methods for predicting trial success before initiation remain limited. Existing artificial intelligence approaches often focus on isolated metrics or specific development stages and frequently rely on variables unavailable at the trial design phase, limiting real-world applicability. We present a hierarchical latent risk-aware machine learning framework for prospective prediction of clinical trial operational success using a curated subset of TrialsBank, a proprietary AI-ready database developed by Sorintellis, comprising 13,700 trials. Operational success was defined as the ability to initiate, conduct, and complete a clinical trial according to planned timelines, recruitment targets, and protocol specifications through database lock. This approach decomposes operational success prediction into two modeling stages. First, intermediate latent operational risk factors are predicted using more than 180 drug- and trial-level features available before trial initiation. These predicted latent risks are then integrated into a downstream model to estimate the probability of operational success. A staged data-splitting strategy was employed to prevent information leakage, and models were benchmarked using XGBoost, CatBoost, and Explainable Boosting Machines. Across Phase I-III, the framework achieves strong out-of-sample performance, with F1-scores of 0.93, 0.92, and 0.91, respectively. Incorporating latent risk drivers improves discrimination of operational failures, and performance remains robust under independent inference evaluation. These results demonstrate that clinical trial operational success can be prospectively forecasted using a latent risk-aware AI framework, enabling early risk assessment and supporting data-driven clinical development decision-making.
Thank you to arXiv for use of its open access interoperability. PaperDance 不是 arXiv 官方产品;中文卡片由大模型生成,请以原文为准。